Gastroenterology and Hepatology From Bed to Bench最新文献

{"title":"A comprehensive review on seroepidemiology and molecular epidemiology of hepatitis E Virus in Iran.","authors":"Amir Hossein Aghapour, Seyed Masoud Hosseini, Shahrzad Shoraka, Amir Ghaemi, Afsaneh Sharifian, Seyed Reza Mohebbi","doi":"10.22037/ghfbb.v18i4.3102","DOIUrl":"10.22037/ghfbb.v18i4.3102","url":null,"abstract":"<p><p>Hepatitis E virus (HEV) is a global threat to human health. The virus can cause acute liver disease in infected people, and although it is self-limiting in most people infected, it can cause serious liver problems and even death in some individuals, including pregnant women. HEV has eight genotypes, but usually four of its genotypes have been reported to cause infection in humans. Hepatitis E is expected to cause 20 million infections worldwide in a year, with 3.3 million symptomatic cases and about 44000 deaths. It's considered endemic in many developing countries, and poses a threat to global health. Mortality among pregnant women and newborns also highlights the importance of the control of the virus and the need for comprehensive techniques to monitor and reduce its spread. One way of transmitting HEV is through contaminated water and food, especially in the event of flooding. In addition, products of raw or undercooked meat from animals such as pigs and camels are likely to be a problem in developed countries. With close monitoring, the global prevalence of HEV can be reduced. It can also be significantly controlled with the availability of effective vaccines and improved hygiene standards. This review focuses on the molecular virology of HEV, pathogenesis, epidemiology, diagnostic methods, transmission routes and treatment options.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 4","pages":"390-412"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in the New Zealand (NZ) healthcare system and health disparities in the Māori population.","authors":"Kamran Rostami, Adele Rostami","doi":"10.22037/ghfbb.v18i4.3277","DOIUrl":"10.22037/ghfbb.v18i4.3277","url":null,"abstract":"","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 4","pages":"369-372"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147347777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of supraglottic airway vs. infraglottic airway in endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis.","authors":"Vanio L J Antunes, Tulio L Correa, Matthew Antony Manoj, Matheus Vanzin Fernandes, Cynthia Florêncio de Mesquita, Otávio Cosendey Martins, Natalia Junkes Milioli, Stefano Baraldo, Sara Amaral, Julio Pereira-Lima","doi":"10.22037/ghfbb.v18i1.3044","DOIUrl":"10.22037/ghfbb.v18i1.3044","url":null,"abstract":"<p><strong>Aim: </strong>To compare the efficacy and safety of supraglottic airway (SGA) vs. infraglottic airway (IGA) in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP).</p><p><strong>Background: </strong>To optimize patient outcomes by improving airway control, various airway techniques have been employed for sedation during ERCP. However, there is uncertainty about the noninferiority of SGA devices compared to IGA.</p><p><strong>Methods: </strong>We performed a systematic review in PubMed, Embase, and Cochrane Library databases, searching for randomized and non-randomized studies comparing SGA vs. IGA in patients undergoing ERCP and reporting at least one of the outcomes of interest. The primary outcomes were procedure time, incidence of hypoxia, and blood staining events. Statistical analyses were performed using R language 4.3.1. Odds ratio (OR) was used for binary outcomes and mean difference (MD) for continuous outcomes with their respective 95% confidence interval (CI). Heterogeneity was assessed using the Cochran Q test and I² statistics.</p><p><strong>Results: </strong>The study comprised 1 randomized controlled trial (RCT) and 3 observational studies involving 280 patients. Among them, 160 were allocated to the SGA group and 120 to the IGA group. When comparing procedure times, there was no statistically significant difference between SGA and IGA (MD -1.51 minutes; 95% CI -6.10 to 3.09 minutes; p = 0.52; I² = 62%). Regarding blood staining, statistical significance favored IGA over SGA (OR 2.67; 95% CI 1.12 to 6.41, p = 0.027; I² = 0%).</p><p><strong>Conclusion: </strong>No statistically significant difference in procedure time was observed between SGA and IGA. However, IGA exhibited a favorable outcome regarding reduced blood staining compared to SGA. Further studies comparing similar outcomes are necessary to assess such associations better.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 1","pages":"32-38"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of circulating uric acid in gastrointestinal cancers, a systematic review and meta-analysis.","authors":"Rozita Khodashahi, Mahdieh Jajroudi, Gordon A Ferns, Mohsen Aliakbarian, Mohammad-Hassan Arjmand","doi":"10.22037/ghfbb.v18i1.2965","DOIUrl":"10.22037/ghfbb.v18i1.2965","url":null,"abstract":"<p><strong>Aim: </strong>Thus, this meta-analysis was performed to assess the prognostic value of serum uric acid in patients with gastrointestinal cancers (GI).</p><p><strong>Background: </strong>There is growing evidence that high serum uric acid may be used as a potential prognostic marker in gastrointestinal malignancies. However, there are inconsistencies in the reported findings.</p><p><strong>Methods: </strong>Related studies were identified by searching the following databases: PubMed, Web of Science, Cochrane Library, and Scopus, independently up until 30 October 2023. Relevant analyses were carried out to deal with heterogeneity in the data. According to the inclusion criteria, we used English original papers reporting prognostic value of serum/plasma uric acid to determine hazard ratio (HR) and 95% confidence interval (CI) in patients with GI cancers. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to ascertain the association of uric acid levels with gastrointestinal cancer (GI) risk. The inconsistency index (I2) was used to calculate the level of heterogeneity among the selected studies. The quality of each study was evaluated by Newcastle-OTTAWA Scales (NOS).</p><p><strong>Results: </strong>A total of 9 papers with 95.285 patients were included in this meta-analysis. The findings indicated a significant association between serum uric acid and poor prognosis in patients with gastrointestinal cancers (HR=1.477, 95% CI 1.165-1.873, P= 0.001). Further, in Subgroup analysis we found that patients would have poor survival rate among different cut-offs of uric acid, ≥ 5mg/dl, HR= 1.403, 95% CI=1.150-1.711, P=0.001 vs cut-off <5mg/dl, HR=1.54, 95% CI=1.140-2.063, P=0.005.</p><p><strong>Conclusion: </strong>Serum uric acid level is significantly linked to survival outcomes in patients with gastrointestinal cancers. Serum uric acid levels may be an effective prognostic marker associated with clinical outcomes in patients with gastrointestinal cancers. Given the small number of studies included in this meta-analysis and high heterogeneity, we suggest that a more comprehensive study is required to achieve more robust results.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 1","pages":"21-31"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antisense RNAs (asRNAs) as key players in gallbladder cancer progression: a bioinformatics analysis.","authors":"Monika Rajput, Ruhi Dixit, Manoj Pandey, Vijay Kumar Shukla","doi":"10.22037/ghfbb.v18i2.3002","DOIUrl":"10.22037/ghfbb.v18i2.3002","url":null,"abstract":"<p><strong>Aim: </strong>This study reports differential expression of Antisense RNAs (asRNAs) by analyzing transcriptomic profiles in gallbladder cancer (GBC).</p><p><strong>Background: </strong>asRNAs play crucial roles in developing various tumors. However, the presence and biological mechanism of asRNAs in GBC development are still unknown.</p><p><strong>Methods: </strong>Differentially expressed asRNAs (DE-asRNAs) were systematically identified from RNA sequencing data from ten GBC patients. Functional enrichment analysis was performed, followed by the identification of mRNAs targeted by asRNAs and the construction of a gene regulatory network of asRNAs targeting mRNAs.</p><p><strong>Results: </strong>Of the 891 asRNAs identified, 17 DE-asRNAs were statistically significant. Out of 17, 12 asRNAs were upregulated, and five asRNAs were downregulated. Functional enrichment analysis showed their role in methylation and developmental processes. Of the 17 asRNAs, 14 are novel (UNC5B-AS1, SLC2A1-AS1, BBOX1-AS1, SOX21-AS1, ELFN1-AS1, TRPM2-AS, DNAH17-AS1, DCST1-AS1, VPS9D1-AS1, MIR1-1HG-AS1, HAND2-AS1, PGM5P4-AS1, PGM5P3-AS1, and MAGI2-AS). Enrichment analysis of asRNAs with target mRNAs showed enrichment in biological regulation and developmental processes involved in the PI3K, p53, apoptosis, and VEGF signaling pathways.</p><p><strong>Conclusion: </strong>This study identified 14 asRNAs for the first time and showed that asRNAs targeting mRNAs strongly associated with tumor development in GBC through the PI3KCA and TP53 pathways.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 2","pages":"216-229"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resting functional magnetic resonance images of the brain in functional gastrointestinal diseases: a concise review of the literature.","authors":"Parsia Noori Mirtaheri, Saba Mehrtabar, Reza Shah Hosseini, Kianoush Shahryari, SeyedAbbas Pakmehr, Arash Rahimi, Sourena Mohammad Hashem, Seyed Amirabbas Shahidi Marnani, Shaghayegh Karami, Mahsa Sadeghi, Yeganeh Azhdary Moghaddam, Aida Azhdari Moghaddam, Niloofar Deravi, Mahsa Asadi Anar","doi":"10.22037/ghfbb.v18i2.2987","DOIUrl":"10.22037/ghfbb.v18i2.2987","url":null,"abstract":"<p><p>Functional gastrointestinal disorders (FGID) are prevalent illnesses associated with diminished quality of life and increased healthcare utilization. These conditions influence gut sensitivity, motility, microbiota, immunological function, and nervous processing in the brain. Chronic symptoms, including pain and dyspepsia, are exacerbated by maladaptive patient behaviors, stress, and co-morbidity. Studies of functional neuroimaging reveal increased brain responses in regions associated with gut sensory processing and salient cues, altered central regulation of endocrine and autonomic nerve responses, and aberrant connections in pain processing and the default mode network. This neuroimaging helps us understand the pathophysiology and outcomes of patients better. From the standpoint of brain connection, research in this area can further our understanding of the central pathophysiology of FGID and pave the way for the objective diagnosis and development of novel therapeutics for FGID. Prospective Neuroimaging research may change from brain mapping to clinical prognosis prediction due to technological advances in machine learning algorithms used in imaging. The usefulness and revelations of functional brain imaging are highlighted in this review, along with the areas that require development and, lastly, recommendations for future research.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 2","pages":"164-176"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of sarcopenia and myosteatosis on overall survival following liver transplantation.","authors":"Pooneh Dehghan, Mehdi Eshaghzadeh, Amirhassan Rabbani, Mahdi Mehrian, Mohsen Kaveh, Mahmoud Amiri, Farshad Shouhani","doi":"10.22037/ghfbb.v18i4.3204","DOIUrl":"https://doi.org/10.22037/ghfbb.v18i4.3204","url":null,"abstract":"<p><strong>Aim: </strong>This study assessed the prognostic value of sarcopenia and myosteatosis for survival following liver transplantation using CT-derived skeletal muscle index (SMI) and skeletal muscle radiation attenuation (SMRA).</p><p><strong>Background: </strong>Sarcopenia and myosteatosis are common in liver transplant (LT) candidates and may affect postoperative outcomes.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed 79 LT recipients (aged 17-75 years) at Taleghani Hospital, Tehran, Iran, from October 2019 to November 2023, excluding patients with malignancy or cardiovascular disease. Non-contrast-enhanced CT scans at the third lumbar vertebra were analyzed using SliceOmatic software to quantify SMI and SMRA. Sarcopenia was defined using AWGS-adapted criteria for CT: low SMI (<42 cm²/m² for men, <38 cm²/m² for women), reduced handgrip strength (<30 kg for men, <20 kg for women), or reduced gait speed (<1 m/s). Sarcopenia was classified as pre-sarcopenia (low SMI), sarcopenia (low SMI with either deficit in hand grip strength or gait speed), severe sarcopenia (low SMI with both deficits), or sarcopenic obesity (sarcopenia with BMI ≥30 kg/m²). Myosteatosis was defined by SMRA (<41 HU for BMI <25 kg/m²; <33 HU for BMI ≥25 kg/m²). The Cox proportional hazards model and Kaplan-Meier analysis assessed survival predictors (P<0.05).</p><p><strong>Results: </strong>Among 79 recipients (58.2% male, mean age 47.2±13.7 years), 77.2% had myosteatosis and 34.2% had pre-sarcopenia. Over 60,173 person-days, 17 deaths occurred. Myosteatosis (HR 2.15, 95% CI 1.03-4.48), elevated bilirubin (HR 1.04, 95% CI 1.02-1.07 per unit), and female sex (HR 2.29, 95% CI 1.19-4.14) were associated with increased mortality hazard (all P<0.05). Kaplan-Meier curves showed 5-year survival of 70-80%.</p><p><strong>Conclusion: </strong>Myosteatosis, elevated bilirubin, and female sex are significant predictors of mortality post-LT in this cohort. CT-derived SMRA assessment offer valuable tools for pre-transplant risk stratification, supporting targeted interventions to improve early outcomes.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 4","pages":"438-445"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probiotics: a supplement to the gluten-free diet in celiac disease.","authors":"Hasna Ait Said, Lahcen Elmoumou, Bouchra Rherissi, Nadia El Kadmiri","doi":"10.22037/ghfbb.v18i3.3145","DOIUrl":"10.22037/ghfbb.v18i3.3145","url":null,"abstract":"<p><p>Celiac disease is an enteropathy caused by intolerance to gluten, with genetic and environmental factors playing a key part in its pathogenesis. This review addresses the use of the gluten-free diet as the primary treatment for patients with celiac disease and the use of probiotics as an adjunctive therapy. The gluten-free diet is the sole treatment for preventing symptoms and allowing the inflamed intestinal mucosa to recover. The gluten-free diet, however, also has some very significant challenges like its complexity, the need for ongoing monitoring by dieticians, and the risk of contamination with gluten even in gluten-free labelled foods. At the same time, the growing interest in the use of probiotics as an adjunct therapy in celiac disease management is based on the hypothetical contribution of the gut microbiota to the pathophysiology of the disease. It has been hypothesized that gut dysbiosis could be involved in the development and maintenance of celiac disease symptoms. Probiotics, in particular the genera <i>Lactobacillus</i> and <i>Bifidobacterium</i>, are among the promising adjuvants for the improvement of gut health. These beneficial microorganisms may play an essential important, crucial role in the breakdown or modification of gluten polypeptides and in the reduction of intestinal epithelial cell damage caused by gliadin. While probiotic use is not a replacement for a gluten-free diet, it can have additive benefits by assisting in the preservation of a healthy balance of gut microbiota and lessening some chronic gastrointestinal symptoms.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 3","pages":"301-308"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12535777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of pancreatic cancer in Iran: an analysis of Global Burden of Disease 2021.","authors":"Mehdi Azizmohammad Looha, Ali Saberi Shahrbabaki, Mahmoud Zamani, Amirali Zareie Shab Khaneh, Sara Javadi, Zahra Sadeghloo, Azin Mohammadpoor, Zahra Sharifi, Alireza Bahadorimonfared, Maryam Gholami Shahrebabak, Mohammad Rostami-Nejad","doi":"10.22037/ghfbb.v18i4.3225","DOIUrl":"10.22037/ghfbb.v18i4.3225","url":null,"abstract":"<p><strong>Aim: </strong>To assess national and provincial trends in pancreatic cancer (PC) incidence, mortality, and mortality-to-incidence ratio (MIR) in Iran (1990-2021) using Global Burden of Disease (GBD) 2021 data.</p><p><strong>Background: </strong>PC is highly lethal, and recent burden estimates for Iran are limited.</p><p><strong>Methods: </strong>Age-standardized and age-specific incidence and mortality rates were obtained from the GBD Results Tool; MIR was calculated. Joinpoint regression was used to estimate average annual percentage change (AAPC) overall, by sex, and in adults aged ≥55 years.</p><p><strong>Results: </strong>From 1990 to 2021, age-standardized incidence and mortality increased by 80% (1.98 to 3.57 per 100,000) and 73% (2.12 to 3.65 per 100,000), respectively, while the MIR declined slightly (1.07 to 1.02) but remained above 1. Among adults ≥55 years, incidence and mortality nearly doubled (8.31 to 16.84 and 8.73 to 17.38 per 100,000, respectively), with minor MIR reductions (1.05 to 1.03). Joinpoint regression confirmed significant national increases in incidence (AAPC:1.88%) and mortality (AAPC:1.73%), alongside a modest decline in MIR (AAPC:-0.14%). Provincially, all regions exhibited rising age-standardized incidence and mortality, most steeply in Ilam and the lowest in Tehran. MIR generally declined, notably in Tehran, Lorestan, and Chaharmahal and Bakhtiari, though slight increases occurred in South/North Khorasan, Markazi, and Sistan and Baluchestan.</p><p><strong>Conclusion: </strong>PC burden in Iran has increased subs`tantially over the past three decades, especially among older adults and in certain provinces. Persistently high MIR indicates late diagnosis and poor survival, highlighting the need to strengthen cancer registries, improve early detection and diagnostic capacity, and address modifiable risk factors.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 4","pages":"455-466"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147347496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of coffee and coffee extract on liver function test in non-alcoholic fatty liver disease ‎patients, a systematic review and meta-analysis.","authors":"Mobina Sayedi, Zahra Chaghazardi, Amin Sharifi","doi":"10.22037/ghfbb.v18i4.3123","DOIUrl":"10.22037/ghfbb.v18i4.3123","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate the effect of coffee or coffee extract on serum ALT and AST levels in patients with non-alcoholic fatty liver disease (NAFLD), by compiling data from randomized controlled trials up to November 2024.</p><p><strong>Background: </strong>NAFLD represents the most prevalent hepatic disorder, characterized by the accumulation of lipids within hepatocytes in the absence of substantial alcohol consumption or viral infections. Effective management relies on lifestyle changes, such as diet and exercise. Recent studies have suggested that coffee consumption may offer liver-protective benefits, potentially helping to reduce serum levels of liver enzymes.</p><p><strong>Methods: </strong>Two researchers conducted an independent search across PubMed, Web of Science, and Scopus, including clinical trials that assessed the effects of coffee or coffee extract on liver function tests (LFTs) in individuals diagnosed with NAFLD. Meta-analysis was carried out using STATA software.</p><p><strong>Results: </strong>After screening titles, abstracts, and full texts, four studies comprising five placebo-treatment pairs were included in the meta-analysis. Coffee or coffee extract did not significantly affect serum ALT (p= 0.45) and AST (p= 0.54) levels.</p><p><strong>Conclusion: </strong>There is insufficient evidence to support the effectiveness of coffee or coffee extract on serum ALT and AST levels. Due to the limited number of studies, small sample sizes, and short follow-up durations, further randomized controlled trials with adequate sample sizes and more extended follow-up periods are recommended.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 4","pages":"373-379"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12920697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147347834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}